INTRODUCTION
Male infants have been consistently noted to have a higher infant mortality rate than female infants. [1] [2] [3] [4] [5] The higher rate of mortality for male infants is present both in the neonatal and the postneonatal period and persists even after other known risk factors for mortality are controlled. 2, 3 In the United States, there has been a steady decline in both neonatal and postneonatal mortality since the 1950s. 6 While the decline in infant mortality prior to 1970 was accompanied by a relative increase in the male excess in mortality, 1 little is known about changes in the sex difference in mortality since that time.
Decreases in infant mortality since the 1970s have largely resulted from improved survival of preterm infants due to significant advances in neonatal treatment, with proliferation of neonatal intensive care units (NICU) and establishment of regionalized perinatal centers beginning in the 1970s. 7 More recently, increased use of antenatal steroids and the availability of surfactant therapy are considered important advances contributing to improved neonatal outcome presumably by decreasing the incidence and severity of conditions associated with preterm births such as respiratory distress syndrome (RDS). [8] [9] [10] [11] [12] [13] Since males are at higher risk of prematurity and prematurity-related conditions such as RDS, 14, 15 it is possible that these advances in therapy could differentially benefit male infants, and as a result, alter the sex difference in mortality.
We investigated changes in the sex difference in infant mortality in Massachusetts between 1989 and 1995 and evaluated changes in disease specific mortality that may have contributed to that change.
METHODS

Study Sample
Linked birth and death certificate data for all births occurring in Massachusetts between 1989 and 1995 obtained from Massachusetts Public Health Statistics Bureau were used to investigate changes in sex difference in neonatal, postneonatal, and infant mortality among liveborn infants. A total of 619,801 live births occurred in Massachusetts between January 1989 and December 1995.
Gestational age data in vital statistics that are normally based on the date of the last menstrual period (LMP) may often be inaccurate. 16 The Massachusetts-linked birth and death certificate data had two sources of information for gestational age, a gestational age based on LMP and a clinical estimate of gestational age. We used both sources of information to evaluate the data to determine the best estimate of gestational age and then excluded infants with implausible gestational ages and implausible birthweight/gestational age combinations. 17 Implausible combinations were based on gestational age specific birth weight ranges determined by Alexander et al. The complete process is shown in Figure 1 .
Overall, 0.65 percent male (N ¼ 2072) and 0.63 percent female (N ¼ 1903) births were deleted from the original linked birth and death data. The final data set consisted of 615,836 infants.
Study Variables
The cause of death categories were based on International Classification of Disease, 9th revision, Clinical Modification (ICD 9 CM). 18 The primary cause of death in the vital statistics data is automatically assigned by using a standardized computer program, the Automated Classification of Medical Entities (ACME). These individual causes were grouped into the following five categories: Respiratory Distress Syndrome (RDS), Congenital Anomalies, Maternal Conditions, Prematurity Related Causes, and ''All Other''. [19] [20] [21] [22] Statistical Analyses Crude comparisons of the sex difference in infant, neonatal, and postneonatal mortality for each year were performed and statistical significance determined using the w 2 -test. We evaluated differences between mortality rates rather than risk ratios because an absolute change in mortality was the outcome of interest. We compared infant mortality for male and female infants by gestational age rather than birth weight categories, since gender comparisons by birthweight may be biased because of the higher male birth weight at each gestational age. Gestational age was considered in three categories: very premature (r30 weeks), moderately premature (31 to 36 weeks) and term (Z37 weeks).
To determine whether there was a systematic change in the sex difference in mortality over time, a nonlinear regression model was used. 23 A nonlinear regression was chosen since it would capture any change in the rate of decline in mortality over time, while a linear regression assumes a constant decrease in mortality during the entire period. The following exponential function was employed:
where, Y represented mortality rate, Sex was entered as a dichotomous variable (female ¼ 0, male ¼ 1) and Year was assigned a value of 0 for 1989 and increased thereafter by 1 for each subsequent year. In the regression, the coefficient b 3 estimated the exponential rate of decrease in mortality each year and in combination with b 1 and b 2 quantified the relative change in mortality for male and female infants each year (i.e., the narrowing or widening of the gap). After performing the overall evaluation, we examined malefemale differences in mortality separately for each gestational age category. To provide more stable estimates, the annual data were combined to form two equal groups of three years each, 1989 to 1991 (earlier years) and 1993 to 1995 (later years). We also examined gender differences in neonatal mortality by race and maternal age. However, the results from these secondary testing should be interpreted with caution because of the increased chance of getting false positives due to multiple testing. The analysis was conducted using SAS statistical software (SAS Institute, Cary, NC).
RESULTS
While infant mortality decreased for both male and female infants during the study period (Table 1, Figure 2a ), the rate of decline was greater for males as compared to female infants. Between 1989 and 1995, male infant mortality declined by 2.5/1000 live births (LB), but the female infant mortality rate decreased only by 1.7/ 1000 LB. As a result, the male excess in infant mortality decreased by 50%, from 1.6/1000 LB in 1989 to 0.8/1000 LB in 1995.
Neonatal and postneonatal mortality also declined for both male and female infants between 1989 and 1995 (Figure 2b , c). However, there was a decrease in the male excess only for neonatal deaths (Table 1) . Between 1989 and 1995, the male neonatal mortality rate declined by 1.5/1000 LB, while female neonatal mortality rate decreased only by 0.9/1000 LB. This resulted in a decrease in the male excess in neonatal mortality from 1.1/1000 LB in 1989 to 0.5/1000 LB in 1995. There was no change in the sex difference in postneonatal mortality. A nonlinear regression model examining neonatal mortality confirmed that between 1989 and 1995 the decrease in neonatal mortality was significantly faster for males compared to females. For 1989 (the baseline year), the model estimated that the male excess in neonatal mortality was 1.1/1000 LB (95% Confidence Interval (CI) for the difference: 0.7, 1.5). As a result of the more rapid decline of male neonatal mortality, the model estimated that by 1995 the male excess became only 0.3/1000 LB.
We then examined the changes in neonatal mortality by gestational age using the 3-year grouped data. The largest decrease in the male excess in neonatal mortality rate between the earlier (1989 to 1991) and later (1993 to 1995) time periods was observed among very premature infants (GA r 30 weeks) ( Table 2) . It resulted from a faster decrease in neonatal mortality of 78.7/ 1000 LB among males compared to a decrease of only 12.7/1000 LB among female infants ( Table 2) . As a result, the male excess in neonatal mortality of 54.1/1000 LB that existed during 1989 to 1991 was no longer present during 1993 to1995. Between 1989 to 1991 and 1993 to 1995 neonatal mortality did not change for moderately premature infants (GA ¼ 31 to 36 weeks). The neonatal mortality among term infants (GA Z 37 weeks) also decreased between 1989 to 1991 and 1993 to 1995, but it decreased similarly for male and female infants and produced no changes in sex difference in neonatal mortality.
Among various causes, the greater decrease in deaths due to RDS among males was largely responsible for the decrease in the sex difference. For infants r30 weeks gestation, this represents the most common cause of death (40% of all deaths during 1989 to 1991 and 31% of all deaths during 1993 to 1995) (Figure 3) . In 1989 to 1991, the gender difference of 34.9/1000 LB in RDS deaths (p ¼ 0.004) accounted for a large proportion (65%) of the total male excess of 54.1/1000 LB in neonatal mortality among infants r30 weeks gestation. Between 1989 to 1991 and 1993 to 1995, the male neonatal mortality from RDS decreased by 48.9/1000 LB, while the female mortality decreased by only 20.4/1000 LB. As a result, by 1993 to 1995 the male excess in neonatal mortality from RDS and related respiratory causes decreased to only 6.3/1000 LB.
Prematurity-related deaths also decreased somewhat more rapidly among males (Figure 3) . The neonatal mortality among male infants from this cause decreased by 12.2/1000 LB between 1989 to 1991 and 1993 to 1995 while among female infants it decreased by 4.7/1000 LB. The decrease in the sex difference in 
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Narrowing of Sex Differences in Infant Mortality neonatal mortality of 7.6/1000 LB for prematurity was, however, much smaller than the decrease of 28.6/1000 LB for RDS. Some change in the sex difference also occurred in the ''All Other'' death category. However, this category consisted of a large number of causes of death each contributing a small number (<5 for each time period). The only cause with more than 5 deaths in each time period, infection (ICD 761), declined similarly in male and female infants.
The decrease in the male excess in neonatal mortality among very premature infants occurred for white population, black population as well as all other races (Table 3) . Decrease in the male excess in neonatal mortality among very premature infants was also found for all maternal age categories (Table 4) .
DISCUSSION
The nearly 50% decrease in the male excess in infant mortality in Massachusetts between 1989 and 1995 is a remarkable development considering the long-standing male disadvantage in infant mortality. The reduction in the male excess in mortality we observed was almost exclusively confined to changes in neonatal mortality among infants r30 weeks gestation. Recent decreases in neonatal mortality have largely resulted from advances in treatment, which concentrate on the needs of these very premature (GA r 30 weeks) infants. Our findings suggest that such treatments may have differentially benefited males. These likely reflect differences in the biological development in male and female infants in utero.
This hypothesis is supported by our finding that a more rapid decline in RDS deaths among male infants was the primary reason for the observed reduction in the sex difference in mortality. RDS is the leading cause of death among very premature (GA r30 weeks) infants and the rate is higher among males. 2, 14, 15 The higher incidence of RDS in males is generally ascribed to a slower rate of lung maturation among male infants.
14 Antenatal steroid and surfactants each independently decreases overall neonatal mortality from RDS and the combined use of the two leads to an additive improvement in the risk of death. 24, 25 While antenatal steroids have been in use since 1972, our data indicate a rapid increase in its use between 1989 to 1991 (4% of birth) and 1993 to 1995 (11% of birth), with a similar increase in use among mothers of male and female infants.
Specific data on trends in the use of surfactants were not available. The FDA approved its use only in August 1990. Our finding of a large decrease in RDS deaths only after 1992 could be related to changes in surfactant use if widespread adoption of surfactant therapy throughout Massachusetts occurred with a time lag. A study among very low birthweight infants in St. Louis also found that only 56% of all infants with diagnosis of RDS admitted to a NICU were administered surfactants during 1991 to 1992. 21 While the majority of the decline in the male excess in deaths was due to RDS, there was also some decline in prematurity-related deaths. While specific interventions responsible for the decrease in prematurity deaths could not be ascertained from the data, it is likely to reflect improvement in neonatal intensive care for very premature births. The greater use of antenatal steroids may also be a significant contributor to the decline since clinical studies have found that use of antenatal steroids were associated with decreased neonatal mortality from a number of prematurity-related conditions. 3, 9, 24 We chose to analyze differences in mortality by gestational age category as comparison by birthweight might introduce a bias. Since male infants have a higher birthweight at each gestational age, comparison of male and female infants of the same birthweight would tend to exaggerate any male disadvantage since males would be of a lower gestational age. However, it is known that in vital statistics data, birthweight recordings tend to be more accurate than recordings of gestational ages. 16 To minimize the impact of likely inaccurate gestational age recordings, we corrected the data using clinical estimates of gestational age for implausible gestational age/birthweight combinations. The same percentage of male and female infants had their gestational age corrected as is to be expected since these inaccuracies should not differ between male and female infants. In using vital statistics data, issues related to reporting must also be considered. Although the underlying cause of death in the linked birth and death data is coded according to very specific algorithm, accurate classification of deaths by individual disease category can be problematic. 26 To minimize incorrect recording of closely related disease categories, we combined the causes of death into broader groups. 21 The linked birth and death data also often undercount use of steroids since it may be under-reported on birth certificates. 19 We could not quantify the extent of this undercount if any. However, any possible errors in recording cause of death or any undercounts in steroid use are unlikely to differ by gender.
We found similar changes in sex differences in neonatal mortality among all racial groups as well as various maternal age categories. Therefore, while our study was conducted with A nonlinear regression performed using these summary data reveals a reduction in the male excess in infant mortality between 1989 and 1995 of 0.6/1000 LB, similar to the 0.8/1000 LB decrease noted in our study. More than half the risk of mortality before reaching the age of 18 years is accounted for by the risk of death among infants younger than 1 year of age. 27 The higher mortality among males results in a smaller proportion of male live births surviving to age 18 years compared to females. Since differences in infant mortality is a major cause for this gender gap in survival rate at age 18 years, a decrease in the gap during infant mortality is likely to affect the sex composition of the active working population of age 18 years onwards.
